Hostname: page-component-8448b6f56d-42gr6 Total loading time: 0 Render date: 2024-04-24T10:30:43.926Z Has data issue: false hasContentIssue false
  • English
  • Français

High rate of linezolid intermediate susceptibility and resistance among enteric vancomycin-resistant Enterococcus (VRE) recovered from hospitalized patients actively screened for VRE colonization

Published online by Cambridge University Press:  15 May 2019

Thomas J. Dilworth ,
Eric T. Beck ,
Rachel A. Pedersen ,
Waseem G. Al-Karkokly ,
Margaret M. Cook ,
Erika K. Aldag ,
David J. Kramer ,
Ajay K. Sahajpal ,
Iram Nadeem  and
Brian P. Buggy
...Show all authors
Thomas J. Dilworth*
Affiliation:
Department of Pharmacy Services, Aurora Health Care, Milwaukee, Wisconsin
Eric T. Beck
Affiliation:
Department of Microbiology, ACL Laboratories, West Allis, Wisconsin
Rachel A. Pedersen
Affiliation:
Department of Abdominal Transplant, Aurora Health Care, Milwaukee, Wisconsin
Waseem G. Al-Karkokly
Affiliation:
Department of Microbiology, ACL Laboratories, West Allis, Wisconsin
Margaret M. Cook
Affiliation:
Department of Pharmacy Services, Aurora Health Care, Milwaukee, Wisconsin
Erika K. Aldag
Affiliation:
Department of Pharmacy Services, Aurora Health Care, Milwaukee, Wisconsin
David J. Kramer
Affiliation:
Department of Critical Care Medicine, Aurora Health Care, Milwaukee, Wisconsin
Ajay K. Sahajpal
Affiliation:
Department of Abdominal Transplant, Aurora Health Care, Milwaukee, Wisconsin
Iram Nadeem
Affiliation:
Infectious Diseases Section, Aurora St Luke’s Medical Center, Milwaukee, Wisconsin
Brian P. Buggy
Affiliation:
Infectious Diseases Section, Aurora St Luke’s Medical Center, Milwaukee, Wisconsin
Charles F. Brummitt
Affiliation:
Infectious Diseases Section, Aurora St Luke’s Medical Center, Milwaukee, Wisconsin
*
Author for correspondence: Thomas J. Dilworth, Email: thomas.dilworth@aurora.org
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Brief
Information
Infection Control & Hospital Epidemiology , Volume 40 , Issue 7 , July 2019 , pp. 821 - 822
Copyright
© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

PREVIOUS PRESENTATION. This work was presented as poster no. 1225 at IDWeek 2018 on October 5, 2018, in San Francisco, California.

References

Reyes, K, Bardossy, AC, Zervos, M. Vancomycin-resistant enterococci: epidemiology, infection prevention, and control. Infect Dis Clin North Am 2016;30:953–965.CrossRefGoogle Scholar
Kelesidis, T, Humphries, R, Uslan, DZ, Pegues, DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011;5 2:228–234.CrossRefGoogle Scholar
Bi, R, Qin, T, Fan, W, Ma, P, Gu, B. The emerging problem of linezolid-resistant enterococci. J Glob Antimicrob Resist 2018;13:11–19.CrossRefGoogle ScholarPubMed
Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 28th ed. CLSI supplement M100. Wayne, PA: CLSI; 2018.Google Scholar
Bagga, B, Buckingham, S, Arnold, S, Nesbitt, A, Guimera, D, Lee, K. Increasing linezolid-resistant Enterococcus in a children’s hospital. Pediatr Infect Dis J 2018;37:242–244.CrossRefGoogle Scholar
Clinical Laboratory Standards Institute. Ad hoc working group to reassess daptomycin breakpoint for enterococci. https://clsi.org/media/2307/2018_june_ast_bpwg_report_2__dapto_ceftaroline_cefiderocol.pdf. Published 2018. Accessed November 26, 2018.Google Scholar
Sader, HS, Farrell, DJ, Flamm, RK, Jones, RN. Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009–2013). J Glob Antimicrob Resist 2015;3:161–165.CrossRefGoogle Scholar
Pfaller, MA, Mendes, RE, Streit, JM, Hogan, PA, Flamm, RK. Five-year summary of in vitro activity and resistance mechanisms of linezolid against clinically important gram-positive cocci in the United States from the LEADER Surveillance Program (2011–2015). Antimicrob Agents Chemother 2017;61:e00609–17.CrossRefGoogle Scholar
Cakirlar, FK, Samasti, M, Baris, I, et al. The epidemiological and molecular characterization of vancomycin-resistant enterococci isolated from rectal swab samples of hospitalized patients in Turkey. Clin Lab 2014;60:1807–1812.CrossRefGoogle ScholarPubMed
Doern, CD, Park, JY, Gallegos, M, Alspaugh, D, Burnham, C-AD. Investigation of linezolid resistance in staphylococci and enterococci. J Clin Microbiol 2016;54:1289–1294.CrossRefGoogle ScholarPubMed